How can the US catch up on biosimilars? – MedCity News

Getty Images

Biosimilars are a growing share of the U.S. pharmaceuticals market. But while there are at least 240 biosimilars in the development pipeline, just nine have achieved FDA approval and only three have reached the market.

What needs to change for more biosimilars to enter the U.S. market?

Read the full story in MedCity News.